Verywell Health on MSN13d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
PharmExec13d
New Spravato Indication Offers Greater Flexibility and Personalization for Patients with Treatment-Resistant Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Medical News Today15d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
BioPharma Dive7d
Shares of psychedelics biotech nearly double on depression data
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
Medindia21d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...
Gizmodo20d
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
The double-blinded, randomized, and controlled trial involved people with treatment-resistant depression, who were assigned to three groups: two groups who received different doses of Spravato ...
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
NBC New York21d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
Previously, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing ...